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Abstract 
 
Anti-angiogenic agents targeting tumour vasculature have an established place in 
clinical practice and new data is constantly emerging.  However, despite rapid clinical 
uptake, a very large number of questions regarding these agents remain unanswered. 
One of the main hurdles in clinical practice is lack of accurate and feasible ways of 
assessing response to drug beyond tumour reduction on conventional imaging.   This 
review summarises recent development in the field of biomarkers of response to anti-
VEGF drugs.  
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Introduction 
The regulatory approval of agents targeting tumour vasculature such as 
Bevacizumab and oral multi-receptor tyrosine kinase inhibitors which include VEGF 
(Vascular Endothelial Growth Factor)  receptors as one of their targets, has changed 
clinical practice swiftly and significantly.  One potential attraction of anticancer agents 
designed against specific target molecules would be the logical design of biomarker 
assays based on some biological aspect of that target.  However, despite rapid clinical 
uptake, a very large number of questions regarding these agents remain unanswered. 
The question marks start at the precise nature of the anti-tumour effect and differential 
efficacy in otherwise similar patients/tumours, mechanisms of synergy with cytotoxic 
agents, optimal dose and scheduling with other targeted agents through to pre-selection 
of patients most likely to benefit from treatment and, probably most importantly at this 
time, accurate and feasible ways of assessing response to drug beyond tumour reduction 
on conventional imaging.   
Vascular Endothelial Growth factor (VEGF or VEGF-A) is a potent 
proangiogenic growth factor expressed by most cancer cells and  some tumour stromal 
cells. It belongs to the platelet-derived growth factor family (PDGF) together with other 
dimeric glycoproteins  such as VEGF-B, VEGF-C, VEGF-D, VEFG-E and placenta 
growth factor (PlGF)1.  
The available anti-VEGF agents act through various mechanisms.  Bevacizumab 
and VEGF-Trap for example are antibodies that target the VEGF ligand. Other agents 
target VEGF receptors or downstream signalling pathways and these include small 
molecule inhibitors (Sunitinib, Sorafenib, Axitinib and Pazopanib), antibodies IMC-
1121b and ribozymes-angiozyme. Bevacizumab treatment has been associated with 
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antitumour responses in most tumours and improves survival in patients with colorectal 
and lung cancer when administered with standard chemotherapy2,3. Broad spectrum 
small molecule inhibitors  such as Sunitinib and Sorafenib have shown high activity in 
renal cell carcinoma and are now accepted first and second line treatments4,5. The 
mechanism of action for antiangiogenic therapies is very complex and incompletely 
understood. The anti-VEGF agents are thought to have direct anti-vascular effects6, they 
inhibit blood-borne endothelial cell precursors7 and lead to tumour microvessel 
‘normalisation’ (pruning the immature and leaky vessels, actively remodelling 
remaining vasculature) enabling efficient delivery of cytotoxic treatments8. Beyond 
these observations predominantly from murine models, no reliable validated serum or 
tissue biomarkers of response to anti-VEGF treatment have emerged. However, there 
are many potential candidates based on both murine and human models. The purpose of 
this review is to summarise recent developments in this field.  
The possible approaches to identify markers of response to anti-angiogenic 
treatment can be divided into four major groups: markers isolated and analysed from 
tumour tissue, blood –based markers, imaging based criteria for response and patient 
factors such as changes on blood pressure.  
 
Tumour derived markers. 
The obvious candidate when trying to define and predict the response to anti-
VEGF treatments would be VEGF expression. VEGF is overexpressed in the majority 
of tumours9,1 but it is also present in stromal cells and vascular endothelium (see figure 
1)9,10,11. It can be easily detected by immunohistochemistry, in situ hybridisation, 
quantitative immunassays, Western blotting or reverse-transcriptase polymerase chain 
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reaction RT-PCR. All of these methods require tumour tissue which is usually available 
before treatment but it is not always practical to obtain tissue during and after treatment, 
restricting their clinical utility. As VEGF is also expressed by benign tissue the 
interpretation of tissue expression and its correlation to clinical outcome has to be 
treated cautiously. Immunohistochemistry based studies can, concurrently, also assess 
other markers such as microvascular density (MVD), perivascular changes, cell 
proliferation, apoptosis and functional as well as genomic abnormalities.  
One of the first studies with Bevacizumab in rectal cancer provided some great 
insight into changes in tumour physiology such as blood perfusion, permeability, 
microvascular density and interstitial fluid pressure (IFP) in correlation with systemic 
responses measured by VEGF levels in blood, numbers of circulating endothelial cells 
and progenitor cells as well as tumour responses12. In a study by  Willet et al. (2004) 
twelve days after Bevacizumab infusion, five out of six patients showed significant 
decreases in tumour blood perfusion (40-44% P<0.05) and blood volume within the 
tumour (16-30% in four of the five patients P<0.05). This was accompanied by 
significant decrease in tumour MVD histologically (29-59% in five patients analysed 
P<0.05). IFP was also reduced and was thought to be caused by ‘normalisation’ of the 
blood vessels within the tumour. However, these results did not correlate with the levels 
of circulating VEGF.  
MVD was initially suggested by many groups as a surrogate measure of 
angiogenesis especially in colorectal cancer, but there are,  however,  many examples of 
positive association between VEGF expression and prognosis13,14  as well as reports of 
lack of any prognostic significance15. MVD as a tissue- based biomarker is only suitable 
for tumours that are easily accessible pre- and post treatment and is unlikely to find its 
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way into routine clinical practice. Apart from the changes in tumour vasculature  the 
tumour cell apoptosis was also measured in situ16. Twelve days after Bevacizumab 
administration a significant increase in tumour cell apoptosis was seen in the biopsy 
tissue. Other surrogate markers measured in the tumour tissue include α-smooth muscle 
actin and angiopoietin-2 expression, both detectable and decreasing after Bavacizumab 
administration but again only measured in patients with easily accessible tumours16.  
A broad –based profile of angiogenic factors and cytokines has recently been 
proposed as a measure of response to antiangiogenic treatment. A study presented by 
Hanrahan et al17 looked at correlation of a profile of cytokine and angiogenic factors 
(C/AF) with response to vandetanib (oral inhibitor of VEGFR, EGFR and RET) in 
patients with non small cell lung cancer. The C/AF consisted of 33 factors including 
VEGF, FGF (fibroblast growth factor), EGF (epidermal growth factor), HGF 
(hepatocyte growth factor), E-selectin, ICAM-1, MMP-9, multiple chemokines and 
interleukins. Plasma of patients treated with vandetanib was collected at baseline, on 
day 8, 22 and 43 of treatment. Several of the C/AF factors were found to be of 
prognostic value with low HGF and interleukin 2 receptor (IL-2R) predictive of benefit 
to antiangiogenic treatment but not chemotherapy. There were also significant gender 
differences in progression free survival (PFS) for patients benefiting from vandetanib. 
This is a very new concept of assessment of response to anti-VEGF treatment which 
warrants further evaluation.  
 
Blood-based markers      
VEGF levels can also be measured in body fluids. Patients with large tumour 
burden and widespread metastatic disease have increased levels of circulating VEGF; 
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there is a negative association between VEGF expression and prognosis18,19. 
Unfortunately detection and precise measurement of VEGF may be inaccurate due to a 
number of factors. The immunoassays used to detect circulating VEGF usually use 
capture antibodies which only detect free VEGF. A significant amount of VEGF is 
bound to plasma proteins such as α2-macroglobulin.  Some of the antibodies are only 
specific for single VEGF isoforms. VEGF can also be released from the platelets and 
leukocytes during blood sampling and handling20-22. Two main isoforms of VEGF that 
are detectable in circulation are VEGF 121 and VEGF 165. Some of the available assays 
only detect VEGF 121  or only VEGF 165  whilst others measure the sum of both 
isoforms22. At present there is no evidence that any of the isoforms has any advantages 
over the other. The serum VEGF concentration increases with clotting duration and 
temperature23 and the VEGF levels found in serum are to a large extent representative of 
VEGF released from platelets during clotting rather than a tumour secreted protein20,24. 
The difficulties associated with the exact measurement of circulating VEGF levels, lack 
of international validated approach defining the standard operating procedures for blood 
handling and processing and the wide variety of commercial kits used for detection of 
circulating VEGF, makes circulating VEGF an unreliable biomarker for routine practice 
or for treatment decisions in clinical trials currently.  
Soluble components of VEGF receptors can be detected in peripheral blood. A 
recently reported study by Rini et al showed a possible application of soluble VEGFR-3 
(VEGF receptor -3 ) and VEGF-C levels as a prognostic marker of response to anti-
VEGF treatment25. In this study sixty one patients with metastatic renal cell carcinoma 
were treated with Sunitinib, a tyrosine kinase inhibitor with anti-VEGF activity. VEGF-
A isoform 165 and 121 were measured together with VEGF-C, soluble VEGF receptor 
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–sVEGFR-3 and placental growth factor (PlGF). Plasma samples were collected on 
days 1, 14, and 28 of cycle 1 and days 1 and 28 of cycles 2 through to 4. The levels of 
these markers were analysed using validated ELISA kits. Significant changes in the 
mean plasma levels of VEGF-A, sVEGFR-3 and PlGF were observed within the first 
cycle of sunitinib treatment. After 28 days VEGF-A levels increased 2.8-fold (range 
0.4-13.6) and PlGF levels increased 3.9-fold (range 0.8-20.4), whereas sVEGFR-3 
levels decreased by 37.6% and VEGF-C levels decreased by 22.7%. The correlative 
analysis showed that patients with baseline sVEGFR-3 and VEGF-C levels less than the 
median baseline values (sVEGFR-3-47000pg/ml and VEGF-C 722,1pg/ml) had longer 
progression free survival (PFS) than patients with higher levels. There was no 
correlation between plasma VEGF or PlGF levels and PFS25.  
Soluble VEGFR-2 (sVEGFR-2) levels have also been evaluated in a clinical 
study in patients with gastrointestinal stromal tumours (GIST)26. The levels of VEGF 
and sVEGFR2 were consistently modulated by treatment; however there was no clear 
correlation with clinical response. Patients with metastatic breast cancer as well as 
patients with neuroendocrine tumours treated with sunitinib also showed decrease in 
plasma of soluble VEGFR-2 and VEGFR-327,28. Renal cell cancer treatment with 
pazopanib also leads to a significant decrease in soluble VEGFR-2 and is associated 
with tumour response (p-0.00002)29. Soluble KIT (tyrosine kinase transmembrane 
receptor) appears to correlate well with clinical responses in breast cancer and in 
GIST27,28,30.  
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Circulating Endothelial Cells 
VEGFR-2 is one of the receptors expressed on endothelial cells31,32. Circulating 
endothelial cells (CEC), as opposed to the soluble VEGF receptors, have also been 
suggested as a surrogate marker of anti-angiogenic activity. CECs are mature 
endothelial cells sloughed off the vessel wall as a result of a vascular damage. A 
population of circulating endothelial cells which is thought to be derived from the bone 
marrow is often referred to as circulating endothelial progenitors (CEP). CECs and 
CEPs are distinct from circulating tumour cells (CTC), which can also be measured in 
the plasma. Increased plasma levels of CECs have been reported in cancer patients and 
the levels appear to increase in response to VEGF33,34. The available assays to 
enumerate CECs and CEPs are not straightforward and are subject to many potential 
errors associated with sampling, preparation and analysis35. One possible reason for 
conflicting results in reported studies is the changing immunophenotype of endothelial 
cells that is dependent on the type of injury to the vessel. The majority of assays define 
the CECs as positive for CD146, CD31 and negative for CD45 marker. CEPs are also 
positive for CD133. There is however some data indicating that CD146 is 
homogenously expressed on vascular endothelium but not on viable CECs36. The 
currently available assays are based on manual or automated immunomagnetic isolation 
or flow cytometry. This system could be used in general hospitals and once validated 
could potentially be of great value. Data emerging in the last 2 to 3 years is encouraging 
but by no means clear. Although in many studies CECs levels correlate with tumour 
progression/response to treatment, same data indicates that the changes depend on the 
type of antiangiogenic agent and on the tumour type37. 
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In pre-clinical models treatment with a targeted VEGFR-2 antibody caused a 
dose-dependent reduction in viable CEPs that paralleled its anti-tumour activity38. In 
human studies the data is accumulating and CECs are increasingly thought to reflect the 
disease status as well as response to antiangiogenic treatment. Metastatic breast cancer 
patients  treated with bevacizumab and erlotinib show clear changes of CECs levels 
comparing to baseline, this is most pronounced in the first 3 weeks of treatment and 
appears to predict response to treatment39. A study of patients treated with letrozole and 
bevacizumab showed that CECs are a biomarker of progression as an increase in CECs 
at week 3 compared to week 0 predicted worse PFS (0.015)40.  
Patients with hepatocellular carcinoma (HCC) who responded to treatment with 
Bevacizumab showed a dramatic drop in CEC levels41. Similarly the CEC levels show a 
significant decrease in patients with metastatic renal cell cancer42, GIST malignancies 
and colorectal cancer26, 37. On the other hand patients with pancreatic cancer responding 
to bevacizumab showed no correlation with CEC levels43. Interestingly CEP levels 
appear to increase in response to treatment with anti-angiogenic agents34,42. An analysis 
of 4 phase II studies by Duda et al37 suggested that CEC and CEP kinetics depend on 
the type of antiangiogenic agent and therefore their biomarker value is deferential. 
Sunitinib induced a sustained decrease in CEPs but not CECs in patients with HCC, 
bevacizumab caused increase in CEPs but not CECs in ovarian cancer, and cediranib 
did not significantly change neither CEPs nor CECs in glioblastoma patients37.  
In summary CEC and CEPs are likely to be helpful in future studies but more 
extensive research is clearly required. 
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Imaging based biomarkers 
An idea that new blood vessels developing within the tumours can be captured 
by imaging techniques has been around for a long time. The tumour supplying blood 
vessels are often dilated and tortuous with abnormal branching patterns, dead ends and 
lack of structure typical for other organs such as presence of arterioles, capillaries and 
venules. The permeability of the new blood vessels is also often much higher. 
Microvessel density has been previously mentioned and can be assessed in biopsy 
samples. A method of measuring microvessel density by various imaging techniques 
would offer a less invasive and more acceptable alternative to the patients. Imaging 
techniques can in theory measure blood volume and blood flow as well as differences in 
blood vessel permeability, vascular size and amount of oxygen in the tissue44. The 
various methods used so far are: magnetic resonance imaging (MRI), computed 
tomography (CT), positron emission tomography (PET) ultrasound and other methods 
such as near-infrared optical imaging.  
 An ultrasound technique is relatively cheap and safe, when used with a contrast 
agent  that can target blood vessels , it can be potentially very effective. A novel 
approach uses contrast-enhancing microbubbles conjugated with antibodies targeting 
newly formed endothelial cells. Willmann et al45 used microbubble technique and 
managed to demonstrate microbubble binding to VEGF receptors on tumour cells in 
vitro and tumour associated endothelium in vivo. A validation of this innovative method 
in clinical trials is still pending.  
 MRI techniques have been used extensively in preclinical and clinical studies. 
MRI allows assessment of vascular changes over time, is safe to use as it does not 
involve ionizing radiation but it is expensive. T1-weighted images are sensitive to the 
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low concentration of gadolinium –based contrast and therefore MRI images can give 
information not only on blood flow and tumour changes but also blood vessel 
permeability. CT scan on the other hand can give more quantitative data on blood flow 
due to the linear correlation between the CT image intensity and concentration of the 
contrast agent. PET scanning can give quantitative data and is very sensitive to minute 
concentrations of tracer molecules44 .  
 One of the first human studies evaluating dynamic contrast-enhanced MRI 
(DCE-MRI) was a study reported by Morgan et al46. The study looked at dose-related 
changes in the contrast-enhancement parameters in DCE-MRI as a biomarker of 
response to an oral VEGF receptor tyrosine kinase inhibitor in the context of phase I 
trial. The study showed a statistically significant relationship between reduction in 
contrast enhancement and disease response to the drug suggesting that this method 
needs further evaluation and could potentially be used as an anti-VEGF treatment 
biomarker of response. Other studies also confirmed relationship of disease response 
and contrast uptake but without a correlation to response rate (see figure 2). The results 
of the studies using  DCE-MRI are certainly very encouraging but require validation 
and further studies are ongoing47-49. Although the initial data shows the feasibility of 
DCE-MRI based biomarkers, the complexity and demand on patient and staff as well as 
considerable expense do not seem to support its use as a practical biomarker used on 
aday-to-day basis.  
  
Biomarkers based on patient related factors such as changes in blood pressure 
have been reported28 there appears to be correlation with response to anti-angiogenic 
 13
agents however the changes are not reliable enough to be used in clinical practice as 
indicators of response. 
 
 
Conclusion  
The identification and validation of biomarkers indicating not only benefit of 
antiangiogenic therapy but capable of directly influencing clinical decisions on dosage 
and scheduling are urgently needed. It remains unclear as to the optimal biomarker for 
this purpose; most likely, the combination of data from tissue, blood and imaging will 
ultimately prove most useful. As well as response, biomarkers of resistance to 
antiangiogenic therapy also need to be considered. Resistance to primary therapy may 
be due to a number of factors including tumours switching to alternate pathways that are 
not targeted by that agent. Emerging data of elevated levels of SDF1 correlating with 
poor outcome in recurrent glioblastoma refractory to Bev, and elevated levels of IL-6 in 
hepatocellular carcinoma resistant to sunitib suggest specific alternate pathways exist, 
can be identified and characterised and themselves be targeted by other antiangiogenic 
agents. 
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